Neurocrine Biosciences (NBIX) Expected to Announce Earnings on Monday

Neurocrine Biosciences (NASDAQ:NBIX) will likely be posting its Q3 2026 results after the market closes on Monday, November 2nd. Analysts expect the company to announce earnings of $1.92 per share and revenue of $1.04 billion for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Monday, November 2, 2026 at 4:30 PM ET.

Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Friday, July 31st. The company reported $2.85 earnings per share for the quarter, topping analysts’ consensus estimates of $1.65 by $1.20. The firm had revenue of $959.00 million during the quarter, compared to the consensus estimate of $891.16 million. Neurocrine Biosciences had a return on equity of 22.43% and a net margin of 20.91%. The firm’s revenue for the quarter was up 39.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.65 earnings per share. On average, analysts expect Neurocrine Biosciences to post $7.72 EPS for the current fiscal year and $9.28 EPS for the next fiscal year.

Neurocrine Biosciences Stock Performance

Shares of NASDAQ NBIX opened at $146.10 on Friday. Neurocrine Biosciences has a 1 year low of $122.14 and a 1 year high of $186.12. The firm has a market cap of $14.85 billion, a P/E ratio of 20.22, a PEG ratio of 0.64 and a beta of 0.40. The stock has a fifty day moving average price of $146.63 and a two-hundred day moving average price of $147.39.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. Zacks Research lowered Neurocrine Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 4th. Piper Sandler lifted their target price on Neurocrine Biosciences from $207.00 to $210.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. Wedbush boosted their price target on shares of Neurocrine Biosciences from $185.00 to $194.00 and gave the stock an “outperform” rating in a research report on Monday, August 3rd. Needham & Company LLC reissued a “buy” rating and issued a $204.00 price target on shares of Neurocrine Biosciences in a report on Friday, October 16th. Finally, Truist Financial upped their price target on shares of Neurocrine Biosciences from $200.00 to $213.00 and gave the company a “buy” rating in a report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Neurocrine Biosciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $201.14.

Insiders Place Their Bets

In related news, insider David W. Boyer sold 826 shares of Neurocrine Biosciences stock in a transaction on Monday, September 14th. The stock was sold at an average price of $157.45, for a total value of $130,053.70. Following the transaction, the insider directly owned 8,722 shares in the company, valued at $1,373,278.90. The trade was a 8.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Matt Abernethy sold 2,311 shares of the business’s stock in a transaction on Monday, September 14th. The stock was sold at an average price of $157.20, for a total value of $363,289.20. Following the sale, the chief financial officer directly owned 42,808 shares in the company, valued at $6,729,417.60. This trade represents a 5.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 4.60% of the stock is currently owned by corporate insiders.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is a San Diego-based biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company’s research programs target conditions in which treatments may address significant unmet medical needs.

Neurocrine’s leading product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease.